CME Group Inc. · CME · FY2026 Q3 · Calendar Q4 2026
CME posts record Q3 volume as products and international growth expand
The supplied analysis supports a constructive operating thesis for CME: strong volume, international expansion, product innovation and margin-efficiency initiatives can support continued growth. The thesis depends on regulatory progress, sustained market activity and successful execution of the technology and clearing roadmap.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about CME FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the current analysis emphasizes record volume across all asset classes, stronger international contribution, additional product launches and progress toward Treasury Link and CME Securities Clearing. It also identifies cloud migration and regulatory execution as more prominent implementation considerations.
Guidance delta
Maintained; no new quantitative guidance change was identified in the supplied analysis.
Key takeaways
- Management described record Q3 volume across all six asset classes, supported by demand for risk management and international growth.
- The product pipeline broadened with Single Stock futures, E-nano Equity Index futures and 24/7 gold and silver contracts; Compute Futures remains subject to regulatory review.
- Treasury Link, cross-margining and technology migration are central to the company’s efficiency and infrastructure roadmap.
- The main watchpoints are regulatory execution, continued market activity and the sustainability of market-data growth.
Management priorities
- Expand new products and 24/7 trading offerings.
- Launch CME Securities Clearing and develop Treasury Link.
- Continue cross-margining and other margin-efficiency initiatives.
- Migrate market platforms to cloud infrastructure while maintaining resilience and latency performance.
Follow CME with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 14, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 9, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Oct 7, 2026 |
| UBS | Neutral | Neutral | Maintain | Oct 5, 2026 |
| TD Cowen | Buy | Buy | Maintain | Oct 5, 2026 |
| Deutsche Bank | Hold | Buy | Downgrade | Aug 19, 2026 |
| JP Morgan | Underweight | Underweight | Maintain | Jul 23, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Jul 23, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 15, 2026 |
| Raymond James | Outperform | Outperform | Maintain | Jul 2, 2026 |
| Keefe, Bruyette & Woods | Outperform | Market Perform | Upgrade | Jun 18, 2026 |
| Rothschild & Co | Buy | Neutral | Upgrade | Jun 11, 2026 |
| Erste Group | Hold | Buy | Downgrade | Jun 5, 2026 |
| Argus Research | Hold | Buy | Downgrade | Mar 4, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Feb 5, 2026 |
| Citigroup | Buy | Neutral | Upgrade | Sep 25, 2025 |
| Oppenheimer | Outperform | Outperform | Maintain | Jul 24, 2025 |
| Redburn Atlantic | Neutral | Buy | Downgrade | Oct 8, 2024 |
| Goldman Sachs | Sell | Sell | Maintain | Oct 3, 2024 |
| Rosenblatt | Sell | Sell | Maintain | Apr 25, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 9, 2023 |
| Atlantic Equities | Overweight | Neutral | Upgrade | Jun 10, 2022 |
| CFRA | Hold | Hold | Maintain | Apr 29, 2020 |
| Berenberg | Hold | Buy | Downgrade | Sep 19, 2019 |
| Bank of America | Neutral | Buy | Downgrade | Jan 11, 2019 |
| Jefferies | Buy | Buy | Maintain | Jul 17, 2017 |
| Keefe Bruyette & Woods | Market Perform | Market Perform | Maintain | Jul 29, 2016 |
| CLSA | Underperform | Underperform | Maintain | Jul 14, 2016 |
| Evercore ISI Group | Buy | Hold | Upgrade | May 8, 2015 |
| Compass Point | Neutral | Neutral | Maintain | Oct 21, 2013 |
| ISI Group | Buy | Neutral | Upgrade | Jun 14, 2013 |
| Macquarie | Neutral | Outperform | Downgrade | May 21, 2013 |
| Evercore Partners | Equal Weight | Overweight | Downgrade | Oct 26, 2012 |
| BGB Securities | Hold | Hold | Maintain | Oct 26, 2012 |
| Stifel Nicolaus | Hold | Buy | Downgrade | Oct 8, 2012 |
| Stifel | Hold | Buy | Downgrade | Oct 8, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $305.98. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Daniel Welden | $315 | $278.03 | +2.9% | Oct 14, 2026 |
| Morgan Stanley | Analyst unavailable | $337 | $276.44 | +10.1% | Oct 9, 2026 |
| Barclays | Analyst unavailable | $281 | $270.18 | -8.2% | Oct 7, 2026 |
| UBS | Alex Kramm | $270 | $263.14 | -11.8% | Oct 5, 2026 |
| Wells Fargo | Daniel Welden | $301 | $265.1 | -1.6% | Oct 1, 2026 |
| Deutsche Bank | Analyst unavailable | $270 | $271.54 | -11.8% | Aug 19, 2026 |
| Morgan Stanley | Michael Cyprys | $330 | $252.8 | +7.9% | Jul 23, 2026 |
| Piper Sandler | Analyst unavailable | $295 | $243.61 | -3.6% | Jul 15, 2026 |
| Morgan Stanley | Analyst unavailable | $324 | $237.46 | +5.9% | Jul 10, 2026 |
| UBS | Alex Kramm | $260 | $236.6 | -15.0% | Jul 6, 2026 |
| Piper Sandler | Patrick Moley | $320 | $248.12 | +4.6% | Jun 17, 2026 |
| Piper Sandler | Patrick Moley | $329 | $267.85 | +7.5% | Jun 15, 2026 |
| Redburn Partners | Analyst unavailable | $323 | $263.8 | +5.6% | Jun 11, 2026 |
| Morgan Stanley | Michael Cyprys | $353 | $282.44 | +15.4% | Apr 23, 2026 |
| Barclays | Analyst unavailable | $316 | $285.71 | +3.3% | Apr 23, 2026 |
| Morgan Stanley | Analyst unavailable | $362 | $294.82 | +18.3% | Apr 10, 2026 |
| UBS | Analyst unavailable | $310 | $297.38 | +1.3% | Feb 6, 2026 |
| RBC Capital | Ashish Sabadra | $302 | $300.42 | -1.3% | Feb 5, 2026 |
| Morgan Stanley | Analyst unavailable | $340 | $294.62 | +11.1% | Feb 5, 2026 |
| Barclays | Benjamin Budish | $312 | $294.62 | +2.0% | Feb 5, 2026 |
| Morgan Stanley | Analyst unavailable | $319 | $273.41 | +4.3% | Jan 15, 2026 |
| Morgan Stanley | Michael Cyprys | $320 | $269.09 | +4.6% | Dec 22, 2025 |
| Barclays | Analyst unavailable | $304 | $272.42 | -0.6% | Dec 12, 2025 |
| Morgan Stanley | Michael Cyprys | $314 | $269.5 | +2.6% | Oct 23, 2025 |
| UBS | Alex Kramm | $280 | $267.81 | -8.5% | Oct 23, 2025 |
| Deutsche Bank | Analyst unavailable | $300 | $269.59 | -2.0% | Oct 23, 2025 |
| Raymond James | Patrick O'Shaughnessy | $307 | $271.45 | +0.3% | Oct 13, 2025 |
| Barclays | Analyst unavailable | $280 | $263.6 | -8.5% | Oct 8, 2025 |
| Morgan Stanley | Analyst unavailable | $312 | $264.46 | +2.0% | Oct 1, 2025 |
| UBS | Alex Kramm | $285 | $261.78 | -6.9% | Sep 8, 2025 |
| Barclays | Benjamin Budish | $298 | $277.18 | -2.6% | Jul 24, 2025 |
| Raymond James | Patrick O'Shaughnessy | $287 | $254.57 | -6.2% | Mar 10, 2025 |
| Oppenheimer | Owen Lau | $258 | $227.43 | -15.7% | Oct 24, 2024 |
| Barclays | Benjamin Budish | $231 | $227.14 | -24.5% | Oct 24, 2024 |
| Citigroup | Christopher Allen | $250 | $223.57 | -18.3% | Oct 3, 2024 |
| RBC Capital | Ashish Sabadra | $235 | $218.47 | -23.2% | Sep 26, 2024 |
| Bank of America Securities | Craig Siegenthaler | $177 | $215.74 | -42.2% | Sep 3, 2024 |
| Deutsche Bank | Brian Bedell | $193 | $198.92 | -36.9% | Jul 25, 2024 |
| Piper Sandler | Patrick Moley | $225 | $199.38 | -26.5% | Jul 25, 2024 |
| Barclays | Benjamin Budish | $209 | $197.25 | -31.7% | Jul 25, 2024 |
| UBS | Alex Kromm | $250 | $203.78 | -18.3% | Jun 5, 2024 |
| Rosenblatt Securities | Andrew Bond | $187 | $212.59 | -38.9% | Apr 25, 2024 |
| Barclays | Benjamin Budish | $228 | $212.59 | -25.5% | Apr 25, 2024 |
| Deutsche Bank | Brian Bedell | $210 | $212.21 | -31.4% | Apr 5, 2024 |
| Credit Suisse | Analyst unavailable | $198 | $174.76 | -35.3% | Feb 7, 2023 |
| Morgan Stanley | Analyst unavailable | $196 | $176.93 | -35.9% | Jan 11, 2023 |
| Piper Sandler | Analyst unavailable | $250 | $171.12 | -18.3% | Dec 19, 2022 |
| Credit Suisse | Analyst unavailable | $210 | $194.69 | -31.4% | Sep 6, 2022 |
| Rosenblatt Securities | Analyst unavailable | $171 | $205.46 | -44.1% | Aug 17, 2022 |
| Deutsche Bank | Analyst unavailable | $212 | $202.14 | -30.7% | Aug 12, 2022 |
| Credit Suisse | Analyst unavailable | $216 | $198.24 | -29.4% | Aug 3, 2022 |
| UBS | Analyst unavailable | $240 | $195.34 | -21.6% | Aug 2, 2022 |
| Morgan Stanley | Analyst unavailable | $226 | $198.5 | -26.1% | Jul 28, 2022 |
| Credit Suisse | Analyst unavailable | $218 | $195.99 | -28.8% | Jul 28, 2022 |
| Morgan Stanley | Analyst unavailable | $242 | $201.51 | -20.9% | Jul 19, 2022 |
| Deutsche Bank | Analyst unavailable | $213 | $203.55 | -30.4% | Jul 13, 2022 |
| Credit Suisse | Analyst unavailable | $233 | $204.36 | -23.9% | Jul 6, 2022 |
| UBS | Analyst unavailable | $246 | $204.36 | -19.6% | Jul 6, 2022 |
| Raymond James | Analyst unavailable | $235 | $204.36 | -23.2% | Jul 6, 2022 |
| Atlantic Equities | Simon Clinch | $235 | $200.43 | -23.2% | Jun 10, 2022 |
| UBS | Analyst unavailable | $258 | $204.68 | -15.7% | Jun 3, 2022 |
| Deutsche Bank | Analyst unavailable | $210 | $190.15 | -31.4% | May 19, 2022 |
| Argus Research | Stephen Biggar | $230 | $200.1 | -24.8% | May 16, 2022 |
| Citigroup | Analyst unavailable | $280 | $223 | -8.5% | Apr 28, 2022 |
| Credit Suisse | Analyst unavailable | $259 | $223.03 | -15.4% | Apr 28, 2022 |
| Raymond James | Analyst unavailable | $254 | $225.93 | -17.0% | Apr 28, 2022 |
| UBS | Alex Kromm | $269 | $237.46 | -12.1% | Apr 5, 2022 |
| Jefferies | Daniel Fannon | $258 | $221.8 | -15.7% | Jan 10, 2022 |
| Berenberg Bank | Eoin Mullany | $190 | $215.65 | -37.9% | Nov 2, 2021 |
| Piper Sandler | Richard Repetto | $230 | $192.18 | -24.8% | Oct 1, 2021 |
| Loop Capital Markets | Kenneth Hill | $151 | $197.42 | -50.7% | Apr 29, 2021 |
| Goldman Sachs | Alexander Blostein | $208 | $194.79 | -32.0% | Apr 28, 2021 |
Track every rating change on CME the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationCME Group Inc., through its various subsidiaries, manages international marketplaces for the exchange of futures and options on futures contracts worldwide. Its extensive array of product offerings includes futures and options linked to a broad spectrum of underlying assets, such as interest rates, equity indices, foreign exchange, agricultural commodities, energy, and metals, alongside fixed-income products.…
Historical context
All CME earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PNFP Pinnacle Financial Partners, Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.7% | +2.3% | PNFP: Strong loan growth and fee income, guidance maintained |
| BPOP Popular, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -2.8% | Popular’s Q3 growth remained solid as public deposits declined |
| BX Blackstone Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +8.4% | Blackstone highlights AI infrastructure and fundraising momentum |
| HBANM Huntington Bancshares Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | +0.5% | Huntington maintains 2027 outlook as fee growth offsets pressure |
| HBAN Huntington Bancshares Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | -0.4% | Huntington Reaffirms 2027 Targets as Fee Growth Supports Outlook |
| HBANP Huntington Bancshares Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | +0.3% | Huntington maintains outlook as growth broadens and fee revenue rises |
Latest beats and misses
Who reports nextBeat on EPS
- PNFPFY2026 Q3 · October 21, 2026+2.7% EPS+2.3% move
- SCCOFY2026 Q3 · October 21, 2026+6.4% EPS-2.1% move
- PKGFY2026 Q3 · October 21, 2026+3.8% EPS+4.2% move
- URIFY2026 Q3 · October 21, 2026+11.3% EPS+3.9% move
- LUVFY2026 Q3 · October 21, 2026+15.6% EPS+4.3% move
- RSFY2026 Q3 · October 21, 2026+17.4% EPS-0.7% move
Missed on EPS
- ROLFY2026 Q3 · October 21, 2026-1.4% EPS+5.6% move
- GGGFY2026 Q3 · October 21, 2026-2.5% EPS-16.6% move
- GL-PDFY2026 Q3 · October 21, 2026-1.2% EPS— move
- GLFY2026 Q3 · October 21, 2026-1.2% EPS-3.8% move
- METAFY2026 Q3 · October 21, 2026-41.4% EPS+0.5% move
- LVSFY2026 Q3 · October 21, 2026-20.9% EPS-1.7% move
Get the CME recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-21T16:02:57.295902+00:00
- FN2 earnings calendar · 2026-10-22T01:23:13.354406+00:00
- Polygon adjusted daily market bars · 2026-10-22T07:50:42.553454+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-22T07:50:42.550826+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-22. For educational purposes only; not investment advice.